ATE405649T1 - Hemmstoff zur diagnose und behandlung von haemophilia a patienten - Google Patents

Hemmstoff zur diagnose und behandlung von haemophilia a patienten

Info

Publication number
ATE405649T1
ATE405649T1 AT99921292T AT99921292T ATE405649T1 AT E405649 T1 ATE405649 T1 AT E405649T1 AT 99921292 T AT99921292 T AT 99921292T AT 99921292 T AT99921292 T AT 99921292T AT E405649 T1 ATE405649 T1 AT E405649T1
Authority
AT
Austria
Prior art keywords
factor viii
human antibody
antibody
specificity
nucleotide sequence
Prior art date
Application number
AT99921292T
Other languages
English (en)
Inventor
Johannes Voorberg
Den Brink Edward Van
Ellen Turenhout
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ATE405649T1 publication Critical patent/ATE405649T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT99921292T 1998-05-08 1999-05-07 Hemmstoff zur diagnose und behandlung von haemophilia a patienten ATE405649T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98201543 1998-05-08

Publications (1)

Publication Number Publication Date
ATE405649T1 true ATE405649T1 (de) 2008-09-15

Family

ID=8233706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99921292T ATE405649T1 (de) 1998-05-08 1999-05-07 Hemmstoff zur diagnose und behandlung von haemophilia a patienten

Country Status (12)

Country Link
US (1) US7364735B1 (de)
EP (1) EP1095143B1 (de)
JP (1) JP2002514422A (de)
AT (1) ATE405649T1 (de)
AU (1) AU760678B2 (de)
CA (1) CA2327587C (de)
CY (1) CY1108568T1 (de)
DE (1) DE69939379D1 (de)
DK (1) DK1095143T3 (de)
ES (1) ES2313783T3 (de)
PT (1) PT1095143E (de)
WO (1) WO1999058680A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382547A (zh) * 2016-12-14 2019-10-25 盼展生物技术有限公司 抗凝血因子viii抗体及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197526B1 (en) * 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
WO2005016455A2 (en) 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
EP1325342A2 (de) * 2000-10-13 2003-07-09 Baxter Aktiengesellschaft Xenogene antikörper-enthaltende plasma-reagenzien und zugehörige methoden
ATE463514T1 (de) * 2002-04-29 2010-04-15 Sanquin Bloedvoorziening ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß)
EP1388544A1 (de) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-Idiotypische Antikörper gegen Factor VIII-Inhibitor und Verwendungen davon
FR2889534B1 (fr) * 2005-08-04 2012-11-02 Lab Francais Du Fractionnement Anticorps anti-idiotypique neutralisant l'activite inhibitrice d'un anticorps inhibiteur du facteur viii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731245A (en) * 1983-12-29 1988-03-15 Kitasato Kenkyusho Vaccine, antigen and antibody for treating microorganisms of the MCLS-type streptococcus sanguis
DE3583750D1 (de) * 1984-01-12 1991-09-19 Chiron Corp Hybridom-zellinien und monoklonale antikoerper gegen faktor-viii-c.
US5543145A (en) 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
US5149637A (en) * 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2114950A1 (en) 1991-08-10 1993-02-11 Michael J. Embleton Treatment of cell populations
CA2125396A1 (en) * 1991-12-10 1993-06-24 Wayne A. Marasco Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof
WO1995008336A1 (en) * 1993-09-22 1995-03-30 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
EP0659766A1 (de) 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
EP0776217A1 (de) 1994-08-19 1997-06-04 Novo Nordisk A/S Ein verfahren zur behandlung eines patienten mittels einer biologisch aktiven verbindung
US6258529B1 (en) 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382547A (zh) * 2016-12-14 2019-10-25 盼展生物技术有限公司 抗凝血因子viii抗体及其用途

Also Published As

Publication number Publication date
DE69939379D1 (de) 2008-10-02
US7364735B1 (en) 2008-04-29
WO1999058680A3 (en) 2001-02-22
ES2313783T3 (es) 2009-03-01
CA2327587C (en) 2011-09-13
PT1095143E (pt) 2008-11-28
EP1095143B1 (de) 2008-08-20
AU3853899A (en) 1999-11-29
WO1999058680A2 (en) 1999-11-18
EP1095143A2 (de) 2001-05-02
CY1108568T1 (el) 2014-04-09
AU760678B2 (en) 2003-05-22
DK1095143T3 (da) 2009-01-05
JP2002514422A (ja) 2002-05-21
CA2327587A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
CY1108568T1 (el) Αναστολεας για διαγνωση και θεραπεια ασθενων με αιμορροφιλια α
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
ATE547523T1 (de) Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE356145T1 (de) Polypeptide zur regenerierung des nervensystems
DE69615185T2 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
GB0426960D0 (en) TGR-3 like protein receptor
ATE427955T1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen
DE602004006566D1 (de) Verfahren zur Diagnose und Behandlung von Metastasen und dafür nützliche Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1095143

Country of ref document: EP